T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.
-
Upload
imogen-malone -
Category
Documents
-
view
214 -
download
0
Transcript of T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.
![Page 1: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/1.jpg)
TRANSPLANTATIONJunior Basic Science
Carla Fisher, MD
12-15-09
![Page 2: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/2.jpg)
TRANSPLANT IMMUNOLOGY
Major antigens responsible for rejection are the genes known as the major histocompatibility complex (MHC)
In humans MHC is known as human leukocyte antigen (HLA) Class I (-A, -B, -C) are found on all nucleated cells Class II (-DR, -DP, -DQ) are expressed on antigen
presenting cells (B lymphocytes, monocytes, dendritic cells)
Can get humoral or cellular (more common) rejection
![Page 3: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/3.jpg)
TRANSPLANT IMMUNOLOGY
Allorecognition recognition of foreign HLA molecules by recipient
T cells
Panel reactive antibody (PRA) Detects presence of donor-specific antibodies by
testing reactivity of the recipient’s serum to a panel of common A, B, and DR antigens
Results expressed as a percentage Higher PRA indicates patient more likely to have
an episode of acute cellular rejection
![Page 4: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/4.jpg)
IMMUNOSUPPRESSION
Induction: administered immediately post operatively to induce immunosuppression (biologic)
Maintenance: to maintain immunosuppression once recovered from OR (non-biologic)
In 1960s, 2 drugs were available. Currently there are 15+ available.
![Page 5: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/5.jpg)
IMMUNOSUPPRESSION
CORTICOSTEROIDS historically first used proven benefits however many side effects, esp in long
term for this reason steroids have been removed from many
newer immunosuppressive protocols first line therapy for acute rejection common side effects:
mild cushingoid facies and habitus acne increased appetite mood changes htn prox muscle weakness glucose intolerance poor wound healing
![Page 6: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/6.jpg)
IMMUNOSUPPRESSION
AZATHIOPRINE (IMURAN) inhibits purine synthesis which inhibits T cells 6-mercaptopurine is active metabolite side effect is myelosuppression
MYCOPHENALATE MOFETIL similar to azathioprine as an anti-metabolite but
is more selective
![Page 7: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/7.jpg)
IMMUNOSUPPRESSION CYCLOSPORINE
binds cyclophilllin and inhibits genes for cytokine synthesis (IL-2) decreases T cell activation
calcineurin inhibitor side effects include nephrotoxicity, hepatotoxicity,
tremors, seizures, hirsuitism
TACROLIMUS (FK-506, Prograf) actions similar to CSA but much more potent calcineurin inhibitor similar SEs to CSA but more GI and neurologic
changes
SIROLIMUS does not affect calcineurin activity
![Page 8: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/8.jpg)
BIOLOGIC IMMUNOSUPPRESSION
ANTITHYMOCYTE GLOBULIN (ATGAM) equine polyclonal antibodies directed against
antigens on T cells must be infused via central line, premedication
with steroids/benadryl induction therapy
THYMOGLOBULIN rabbit polyclonal antibodies similar to ATGAM, may be more effective
![Page 9: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/9.jpg)
MONOCLONAL ANTIBODY IMMUNOSUPPRESSION
used for prevention and treatment of acute (severe) rejection
Muromonab-CD3 anti-CD25 mAbs (basiliximab and daclizumab) humanized anti-CD52 mAb alemtuzumab
(Campath-1H) anti-CD20 (rituximab) anti–lymphocyte function-associated antigen-1
(anti–LFA-1) anti–intercellular adhesion molecule-1 (anti–
ICAM-1) anti–tumor necrosis factor alpha (TNF-α)
(infliximab)
![Page 10: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/10.jpg)
TYPES OF REJECTION Hyperacute:
occurs within minutes caused by preformed abs that should be picked
up by crossmatch Accelerated acute:
occurs within first few days cellular and antibody mediated response caused by sensitized T cells to donor antigens
Acute: less common with modern immunosuppression within days to months after transplantation predominantly a cell mediated process,
lymphocytes usually manifested with abnormal laboratory
values but pt asymptomatic Chronic:
months to years after transplant increasingly common problem multifactorial
![Page 11: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/11.jpg)
WHICH OF THE FOLLOWING STATEMENTS REGARDING KIDNEY TRANSPLANTATION IS/ARE TRUE?
A. The one year actuarial survival rate for all patients is greater than 95%
B. The survival rate following transplantation appears to be improved only in diabetic patients
C. The primary cause of graft loss after 5 years is chronic rejection
D. Treatment of chronic refection has improved significantly over the past 10 years
E. Treatment of renal failure with transplantation becomes cost effective at the end of the second transplant year
![Page 12: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/12.jpg)
KIDNEY TRANSPLANTATION currently approx 70,000 patients awaiting
kidney transplant mortality usually related to stroke/MI attach to iliac vessels, usually on the R post op UOP impt to assess graft (must know
pre operative UOP) decreased UOP post kidney transplant?
hypovolemia vascular thrombosis bladder outlet obstruction ureter obstruction drug toxicity acute rejection
![Page 13: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/13.jpg)
KIDNEY TRANSPLANTATION - COMPLICATIONS
Urologic can be due to poor blood supply to ureter drainage and stenting usually 1st line treatment
Vascular complications renal artery (1%) or vein thrombosis renal artery stenosis
Lymphocele incidence 0.6% -18%
Rejection Usually represented by ↑ Cr w/u includes US and biopsy 5 year graft survival 65% cadaveric, 75% living
![Page 14: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/14.jpg)
ALLOCATION OF CADAVERIC RENAL ALLOGRAFTS IS DEPENDENT ON WHICH OF THE FOLLOWING?
A. Time on hemodialysisB. HLA compatibilityC. Recipient’s ageD. PRA resultsE. Region of transplant center
![Page 15: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/15.jpg)
PANCREAS TRANSPLANTATION
commonly done simultaneously with kidney tx
do pancreas tx alone when pt’s diabetes severe enough to warrant immunosuppression
need donor celiac, SMA, portal vein
![Page 16: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/16.jpg)
PANCREAS/KIDNEY TRANSPLANTATION
Successful tx results in: Stabilization of retinopathy ↓ neuropathy ↑ nerve conduction velocity ↓ autonomic dysfunction (gastroparesis) ↓ orthostatic hypotension
No reversal of vascular disease
![Page 17: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/17.jpg)
PANCREAS TRANSPLANTATION - COMPLICATIONS
*common Thrombosis (6%) Hemorrhage Infection Pancreatitis Rejection
![Page 18: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/18.jpg)
ISLET CELL TRANSPLANTATION
Utilizes islets of Langerhans Still requires immunosuppression In 1995, a report of the International Islet
Transplant Registry indicated that of 270 recipients, only 5% were insulin independent at 1 year posttransplant.
![Page 19: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/19.jpg)
LIVER TRANSPLANTATION
Used for acute and chronic liver disease Hepatitis (most common indication) ETOH (must be abstinent x 6 mos) Primary biliary cirrhosis, primary sclerosing
cholangitis Biliary atresia Hepatocellular CA
Single tumor < 5cm Up to 3 tumors < 3cm
APACHE score – best predictor of 1 year survival
Model for End stage Liver Disease
![Page 20: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/20.jpg)
LIVER TRANSPLANTATION – POSTOPERATIVE CARE
Serial laboratory check Coags Bilirubin Glucose LFTs
![Page 21: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/21.jpg)
LIVER TRANSPLANTATION - COMPLICATIONS
Bile leak (#1) – PTC, stent Primary nonfunction – requires
retransplantation Hepatic artery thrombosis Abscesses IVC stenosis cholangitis
![Page 22: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/22.jpg)
REGARDING LIVER TX FOR PATIENTS CHRONICALLY INFECTED WITH HEPATITIS C VIRUS, WHICH OF THE FOLLOWING STATEMENTS IS/ARE TRUE?A. Post-transplant re-infection with hepatitis C
virus occurs in all patientsB. Post-transplant re-infection with hepatitis C
virus can be prevented with combination therapy with interferon and ribavirin and hyperimmunoglobulin
C. Post-transplant re-infection with hepatitis C virus causes cirrhosis in approximately 30% of patients at 5 years after liver transplantation
D. The clinical course of hepatitis C after re-infection is more virulent than that of the original infection
![Page 23: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/23.jpg)
INFECTIONS
Bacterial More likely to occur immediately post transplant Prevention of pneumocystis pneumonia with
Bactrim Viral
CMV Fungal
Mortality 20%
![Page 24: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/24.jpg)
WHICH OF THE FOLLOWING STATEMENTS IS/ARE TRUE REGARDING CMV INFECTION?
A. infection with CMV following kidney transplantation is the strongest predictor of poor long-term survival
B. The incidence of symptomatic CMV infection is declining owing to the utilization of screening tests
C. Patients at highest risk for developing CMV infection are those who test seropositive for CMV IgG
D. CMV infection is more likely to cause chronic allograft nephropathy than infection with BK virus
E. CMV infection can be indistinguishable from acute EBV infection
![Page 25: T RANSPLANTATION Junior Basic Science Carla Fisher, MD 12-15-09.](https://reader035.fdocuments.in/reader035/viewer/2022062715/56649d895503460f94a6e30c/html5/thumbnails/25.jpg)
MALIGNANCY
Non-melanomatous skin cancers – 3-7x more likely
Post transplant lymphoproliferative disorder – 2-3x more likely EBV
Gynecologic/urologic cancers Kaposi’s sarcoma